Candidate Compounds Covid19
reviews & screen candidate compounds covid19
32226821 2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
32292689 ä. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
32318328 ä. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19
32152082 2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
32232214 2020. Potential Treatments for COVID-19; a Narrative Literature Review
32134278 2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)
32375268 2020. Coronavirus Pandemic-Therapy and Vaccines
31996494 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV)
32334062 ä. Current status of potential therapeutic candidates for the COVID-19 crisis
32347359 ä. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19
32162456 2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1 3 Billion Compounds
32194980 2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Icatibant bradykinin antagonist
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
Arbidol retarget influenza
32373347 2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?
Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19
Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen
Glutathione GSH antioxidant
- found in a forrest gump mode
- Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases
Chlorpromazine retarget
Zinc add-on
Selenium
32342979 ä. Association between regional selenium status and reported outcome of COVID-19 cases in China
Remdesivir retarget
32283108 ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
32020029 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Lauric acid nat. compd.
Nicotine nat. toxin
Niclosamide
32125140 ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
Microbiome as target
32356654 ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles
ACE2 as target
32286790 ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2
32333836 ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Garlic extracts
32363255 ä. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil
Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
stem cells
32257554 2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
32257537 2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
32283815 2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use
Ivermectin
32330482 ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors responses
Various Leads
- 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone
- paper in nature
32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Interferons
32275914 2020. Type 1 interferons as a potential treatment against COVID-19
32360182 2020. Antiviral activities of type I interferons to SARS-CoV-2 infection
Plasmapheresis
Reconvalescent sera
32243945 ä. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection
Therapeutic antibodies (virus-targeted)
32375025 ä. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Therapeutic antibodies and biologicals (cytokine/sugnal transduction)
32247642 ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
32241793 2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
32243501 2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
CRISPR genome editing technology
32353252 ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Virus interference
32071427 2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses
Other antirheumatic compounds
Hydroxy-Chloroquine
- check retina status; monitor rhythm known toxicity
- 91% benefit
- approval russia
- scale up production
- on safety, trial
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 substance is useless.
32232419 ä. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know
32227189 ä. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19
32147496 2020. Of chloroquine and COVID-19
32074550 2020. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
32321905 2020. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
32281583 2020. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)
32265182 2020. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
32194981 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
Chemoprevention Covid19
Antiviral agents Covid19
32231345 2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Lung regeneration and repair after Covid19
resilience enhancement
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32311498 ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
psychoneuroimmunology
32234338 ä. Using psychoneuroimmunity against COVID-19
cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
Complementary & Traditional chinese medicine & Ethnopharm
32245701 ä. Is traditional Chinese medicine useful in the treatment of COVID-19?
32233641 2020. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19
32229706 2020. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
32037389 2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
32334064 ä. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet
Exercise
32311497 ä. The immunological case for staying active during the COVID-19 pandemic
Topical agents opening up the world of nano...
Anticoagulants
Vaccination Covid19
32105090 2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
32183941 2020. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2
